Navigation Links
Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis

psing forms of MS. TYSABRI increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Patients should be monitored at regular intervals for any new or worsening signs or symptoms suggestive of PML Because of the increased risk of PML, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate MS therapies. It is available in the US only through a restricted distribution program called the TOUCH Prescribing Program. According to product labeling, after two years, TYSABRI treatment led to a 67% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42% (p<0.001). TYSABRI treatment also resulted in sustained and statistically significant reductions in brain lesion activity as measured by MRI. Changes in MRI findings often do not correlate with changes in the clinical status of patients (e.g., disability progression). The prognostic significance of the MRI findings in these studies has not been evaluated.

In the European Union, TYSABRI is indicated as a single disease-modifying therapy in highly active relapsing-remitting MS patients. Because of the increased risk of PML, it is for patients with high disease activity despite treatment with a beta-interferon or in patients with rapidly evolving severe relapsing-remitting MS.

According to product labeling in the EU, after two years, TYSABRI treatment led to a 68% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001).

Serious adverse events that occurred in TYSABRI-treated patients included hypersensitivity reactions (e.g., anaphylaxis), infections, depression and gallstones. In MS trials, the incidence and rate of other serious and common adverse events, including the overall incidence and rat
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/28/2014)... and NEW PROVIDENCE, N.J. , July ... are invited to meet with Linde,s Healthcare division ... to be held at McCormick Place in ... "Hospitals demand nothing less than complete confidence in ... , Linde,s Healthcare Segment manager. "Linde understands the importance ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Depression Therapeutics ... 2018 http://www.reportlinker.com/p0656880/Depression-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Market Forecasts to 2018 ...
... Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par ... announced that it filed a declaratory judgment complaint and ... in Washington, D.C. seeking to preserve Par,s First Amendment ... healthcare providers about the FDA-approved, on-label use of Par,s ...
Cached Medicine Technology:Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 2Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 3Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 4
(Date:7/28/2014)... 2014 This is a professional ... Tadalafil industry. The report firstly reviews the basic ... manufacturing technology. The report then explores global and ... specification, capacity, Production value, and market share etc. ... and China’s total market of Tadalafil by calculation ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Mahendra Trivedi, ... hosted the Trivedi Online Workshop ‘Consciousness is Power’ on ... (EST). During this workshop, participants from all over the ... of making a deeper connection to their inner guidance ... participants explored the various advantages of raising consciousness and ...
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... Wisconsin (PRWEB) July 28, 2014 ... business process outsourcing (BPO) for Fortune 500 brands, announced ... jobs across its locations in Wisconsin, California, Florida and ... be based at its Neenah campus. , A majority ... which have seasonal ramp-ups that require additional staffing in ...
(Date:7/28/2014)... Community Health Center of Snohomish County (CHC), ... services, has released an article designed to educate patients ... Founded in 1983, the health center has a strong ... that face barriers to obtaining high quality yet affordable ... the CHC, click here: http://www.chcsno.org/locations.ashx?p=1099 , The ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 4Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 3Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3
... 30 years of HIV on an area once described as ... at a lecture hosted by the University of East Anglia ... production, with dire consequences for rural livelihoods, were originally predicted ... AIDS in central and south western Uganda. However, recent research ...
... , THURSDAY, Nov. 11 (HealthDay News) -- Researchers have pinpointed ... (AKI), a finding they believe could lead to a simple ... AKI usually doesn,t show obvious physical symptoms, which is ... The study found that urine samples from mice and ...
... 11, 2010 A new study from researchers in Colorado ... likely to undergo a screening colonoscopy than those who were ... female endoscopists seem to be common among women. In this ... that rates of screening colonoscopy can be increased by offering ...
... THURSDAY, Nov. 12 (HealthDay News) -- If you want to be ... people,s minds drifted from the task or activity at hand, they ... whatever they were doing. The human mind is uniquely capable ... to anticipate things that will happen, and to plan for things ...
... Gardner HealthDay Reporter , THURSDAY, Nov. 11 (HealthDay ... plans will come across some changes as they choose a ... open enrollment period, but experts say those differences won,t be ... Dec. 31, and any changes will take effect Jan. 1, ...
... "This ESMO-symposium will allow bed-side oriented oncologists to ... All presentations will have a clear focus towards ... the major consequences that new developments in cancer ... Soria, Symposium Co-Chair The ESMO Symposium on ...
Cached Medicine News:Health News:30 years on in the epicenter of the African AIDS epidemic 2Health News:Urine Markers May Reveal Kidney Damage Earlier 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Happiness Is a Focused Mind 2Health News:Happiness Is a Focused Mind 3Health News:Medicare Part D Changes Not Overwhelming, Experts Say 2Health News:Medicare Part D Changes Not Overwhelming, Experts Say 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: